Disruptor: Computational Identification of Oncogenic Mutants Disrupting Protein-protein and Protein-DNA Interactions

Overview

Journal Commun Biol

Specialty Biology

Date 2023 Jul 13

PMID 37443295

Authors

Valentina Kugler

Andreas Lieb

Nathan Guerin

Bruce R Donald

Eduard Stefan

Teresa Kaserer

Affiliations

Soon will be listed here.

Abstract

We report an Osprey-based computational protocol to prospectively identify oncogenic mutations that act via disruption of molecular interactions. It is applicable to analyse both protein-protein and protein-DNA interfaces and it is validated on a dataset of clinically relevant mutations. In addition, it is used to predict previously uncharacterised patient mutations in CDK6 and p16 genes, which are experimentally confirmed to impair complex formation.

Citing Articles

Decoding the functional impact of the cancer genome through protein-protein interactions.

Fu H, Mo X, Ivanov A Nat Rev Cancer. 2025; 25(3):189-208.

PMID: 39810024 DOI: 10.1038/s41568-024-00784-6.

DexDesign: an OSPREY-based algorithm for designing de novo D-peptide inhibitors.

Guerin N, Childs H, Zhou P, Donald B Protein Eng Des Sel. 2024; 37.

PMID: 38757573 PMC: 11099876. DOI: 10.1093/protein/gzae007.

References

Shi Y, Hata A, Lo R, Massague J, Pavletich N . A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997; 388(6637):87-93. DOI: 10.1038/40431. View

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

Al-Numair N, Martin A . The SAAP pipeline and database: tools to analyze the impact and predict the pathogenicity of mutations. BMC Genomics. 2013; 14 Suppl 3:S4. PMC: 3665582. DOI: 10.1186/1471-2164-14-S3-S4. View

Li Z, Ivanov A, Su R, Gonzalez-Pecchi V, Qi Q, Liu S . The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nat Commun. 2017; 8:14356. PMC: 5316855. DOI: 10.1038/ncomms14356. View

Muller P, Vousden K . p53 mutations in cancer. Nat Cell Biol. 2012; 15(1):2-8. DOI: 10.1038/ncb2641. View

Cho Y, Gorina S, Jeffrey P, Pavletich N . Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994; 265(5170):346-55. DOI: 10.1126/science.8023157. View

Kaserer T, Blagg J . Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. Cell Chem Biol. 2018; 25(11):1359-1371.e2. PMC: 6242700. DOI: 10.1016/j.chembiol.2018.07.013. View

Yarbrough W, Buckmire R, Bessho M, Liu E . Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst. 1999; 91(18):1569-74. DOI: 10.1093/jnci/91.18.1569. View

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

10.

Goldstein A, Xiao Y, Sampson J, Rotunno M, Bennett H, Wen Y . Rare germline variants in known melanoma susceptibility genes in familial melanoma. Hum Mol Genet. 2017; 26(24):4886-4895. PMC: 5886297. DOI: 10.1093/hmg/ddx368. View

11.

Taylor 4th C, Cormier K, Keenan S, Earnest S, Stippec S, Wichaidit C . Functional divergence caused by mutations in an energetic hotspot in ERK2. Proc Natl Acad Sci U S A. 2019; 116(31):15514-15523. PMC: 6681740. DOI: 10.1073/pnas.1905015116. View

12.

Ruas M, Brookes S, McDonald N, Peters G . Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene. 1999; 18(39):5423-34. DOI: 10.1038/sj.onc.1202918. View

13.

Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y . Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Nat Genet. 2021; 53(3):342-353. PMC: 8237108. DOI: 10.1038/s41588-020-00774-y. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Guerin N, Feichtner A, Stefan E, Kaserer T, Donald B . Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. Cell Syst. 2022; 13(10):830-843.e3. PMC: 9589925. DOI: 10.1016/j.cels.2022.09.003. View

16.

Peters M, Yang Y, Wang B, Fusti-Molnar L, Weaver M, Merz Jr K . Structural Survey of Zinc Containing Proteins and the Development of the Zinc AMBER Force Field (ZAFF). J Chem Theory Comput. 2010; 6(9):2935-2947. PMC: 2941202. DOI: 10.1021/ct1002626. View

17.

Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W . Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27(3):221-34. DOI: 10.1007/s10822-013-9644-8. View

18.

Hallen M, Martin J, Ojewole A, Jou J, Lowegard A, Frenkel M . OSPREY 3.0: Open-source protein redesign for you, with powerful new features. J Comput Chem. 2018; 39(30):2494-2507. PMC: 6391056. DOI: 10.1002/jcc.25522. View

19.

Gensini F, Sestini R, Piazzini M, Vignoli M, Chiarugi A, Brandani P . The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy. Melanoma Res. 2007; 17(6):387-92. DOI: 10.1097/CMR.0b013e3282f1d328. View

20.

Lilien R, Stevens B, Anderson A, Donald B . A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. J Comput Biol. 2005; 12(6):740-61. DOI: 10.1089/cmb.2005.12.740. View